Navigation Links
Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2010
Date:2/25/2011

DUBLIN, Feb. 25, 2011 /PRNewswire/ -- Warner Chilcott plc (Nasdaq: WCRX) today announced its results for the quarter and year ended December 31, 2010. As discussed more fully below, our financial position and results of operations in the quarter ended December 31, 2010 as compared to the prior year quarter were significantly impacted by several important transactions in 2009 and 2010. These transactions included our acquisition of Novartis Pharmaceuticals Corporation's ("Novartis") U.S. rights to ENABLEX in October 2010, our acquisition of the global branded prescription pharmaceuticals business ("PGP") from The Procter & Gamble Company ("P&G") in October 2009 (the "PGP Acquisition"), and our termination of our exclusive license to distribute LEO Pharma A/S's ("LEO") DOVONEX, TACLONEX and pipeline dermatology products in the U.S. and sale of certain related assets to LEO for $1.0 billion in cash in September 2009 (the "LEO Transaction").

Revenue in the quarter ended December 31, 2010 was $694.4 million, a 1% increase over the prior year quarter. The primary drivers of the increase in revenue were products acquired from P&G and Novartis, primarily ASACOL and ENABLEX, which together contributed $91.4 million of revenue growth in the quarter ended December 31, 2010, compared to the prior year quarter. LOESTRIN 24 FE also contributed $17.3 million of revenue growth in the quarter ended December 31, 2010 compared to the prior year quarter. The growth delivered by these products was offset, in part, by the loss of revenues relating to our former products DOVONEX and TACLONEX, which totaled $82.1 million in the quarter ended December 31, 2009. In connection with the LEO Transaction, we entered into a distribution agreement pursuant to which we purchased inventories of DOVONEX and TACLONEX from LEO and distributed them in the U.S.
'/>"/>

SOURCE Warner Chilcott plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine technology :

1. Warner Chilcott to Present at the Citi 2011 Global Health Care Conference
2. Warner Chilcott Announces Earnings Release Date and Conference Call for Fourth Quarter and Full Year 2010 Financial Results
3. Warner Chilcott to Present at the 29th Annual J.P. Morgan Healthcare Conference
4. Warner Chilcott to Present at the Bank of America Merrill Lynch Credit Conference
5. Warner Chilcott Announces FDA Approval of New Oral Contraceptive
6. Warner Chilcott Completes Acquisition of U.S. Rights to Enablex® Overactive Bladder Treatment for $400 Million in Cash
7. Warner Chilcott Announces Settlement with Lupin of Loestrin® 24 Fe and Femcon® Fe Patent Litigations
8. TaiGen Amends Global License Agreement with Warner Chilcott plc for Development and Commercialization of Nemonoxacin -- a New Generation Quinolone Antibiotic
9. Warner Chilcott Announces FDA Approval of Next Generation Actonel
10. Warner Chilcott Announces the Closing of its $500 Million Senior Notes Offering
11. Warner Chilcott Announces Pricing of $500 Million of Senior Notes in Connection with Agreement to Acquire U.S. Rights to Enablex®
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... , September 30, 2014 ... report the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, ... Kits, and Reagents], Application (Immunology, Oncology) & ... 2019", published by MarketsandMarkets, provides a detailed ... opportunities, current market trends, and strategies impacting ...
(Date:9/30/2014)... 30, 2014   Easy Breathe , the fastest ... announced that it now offers the revolutionary AirSense ... the first sleep apnea therapy devices with internal cellular ... to track and share real-time data on each user,s ... CPAP therapy.  In addition, the internal modem allows the ...
(Date:9/30/2014)... 30, 2014 The Chinese wound care market ... rise in the incidence of lifestyle diseases, coupled with ... affordability of better quality of wound care products provide ... coverage of public health insurance schemes and increased reimbursement ... Based on the findings of primary and secondary researches, ...
Breaking Medicine Technology:Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4China Wound Care Market 2China Wound Care Market 3
... today announced that it has received approval from the U.S. Food & Drug Administration to market Alprazolam orally disintegrating tablets. Distribution of the product will commence immediately.   , ... ... ... ...
... Inc. (Nasdaq: MITI ) announced today the closing of its previously announced underwritten public offering. Prior to closing, the ... sold a total of 11.5 million shares of its common stock at a public offering price of $7.00 ... ... , , ...
Cached Medicine Technology:Actavis Receives Approval of Alprazolam ODT in the U.S. 2Actavis Receives Approval of Alprazolam ODT in the U.S. 3Micromet Closes $80.5 Million Public Offering of Common Stock 2Micromet Closes $80.5 Million Public Offering of Common Stock 3Micromet Closes $80.5 Million Public Offering of Common Stock 4
(Date:10/1/2014)... Insuranceragents.info has released a new blog post explaining how ... family members. , Life insurance plans provide important financial ... should always carry a life insurance policy as their ... the family. , Clients can choose from several ... coverage or from a permanent policy. No medical exam ...
(Date:10/1/2014)... ATLANTA (PRWEB) October 01, 2014 ... executive networking and relationship-marketing firm, announced today ... Security Executive® and Project of the Year ... decision makers representing organizations in financial services, ... include large-scale technology endeavors that address key ...
(Date:10/1/2014)... Between 23 million and 50 million ... to figures from the National Institutes of Health (NIH) ... many of them have something else in common: They ... disease. Gluten Free Therapeutics, makers of CeliVites ... disease by publishing a series of blog posts aimed ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Scientists at ... three drugs that target immune system proteins has the ... has just posted details of the new study on ... now. , Researchers in the UWA School of ... anti-CTLA-4 drugs to mice with mesothelioma with promising results. ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 Woodland ... speak to a group of dental specialists who treat ... northern Spain city of Oviedo. Dr. Reshad of the ... lecturer with clients on two continents, will give a ... aesthetic full mouth reconstruction. , “These specialists want to ...
Breaking Medicine News(10 mins):Health News:Life Insurance for Families - Clients Can Compare Affordable Rates Online! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 2Health News:Informative New Blog Series Underscores Link Between Celiac Disease and Other Autoimmune Disorders 3Health News:New Mesothelioma Study Says Mice Cured by Immuntherapy “Cocktail”, Reports Surviving Mesothelioma 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 2Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 3Health News:Woodland Hills Dental Implants Expert Training Dental Specialists in Spain Later This Week 4
... the combination of chemotherapy with a new medication could ... the study of close to 1,000 patients, the overall ... chemotherapy and the oral drug uracil-tegafur. Results of the ... died within five years compared to 89 patients who ...
... Researchers say , the leading cause of blindness for ... macular degeneration // is the leading cause of blindness ... causes of blindness for blacks. ,More than 50 ... because of macular degeneration. In contrast, more than 60 ...
... Americans undergo balloon angioplasty to clear blocked arteries. In many ... may change the outcome of the procedure. ,John ... to avoid a second open-heart surgery. Eight years ago, he ... this year, Bailey had the same kind of chest pain. ...
... on the results of a recent study researchers offer ... of stretching before exercising.// Specialists say stretching does not ... shows static stretching makes muscles weaker for 10 to ... injury. They say some likely causes of injuries include ...
... Diabetic retinopathy is one of the leading causes of blindness ... the retina and the light-sensitive // layer of cells at ... with long-standing diabetes but its incidence can be reduced with ... shows approximately 4.1 million Americans, age 40 or older, suffer ...
... to offer good news for older adults .The first ... in the elderly. Researchers studied nearly 140 adults over ... major depression, while the other half suffered from minor ... had an annual income of less than $10,000. ...
Cached Medicine News:
... Our Shortest, Lightest Pipettor , , The ... perfect example of how our face-to-face relationship with ... new products that make pipetting easier and more ... single channel pipettors., Gets you closer to ...
Single channel module for Finnpipette Biocontrol - Universal handle sold separately...
... The Research pro Electronic Pipette is ideal ... laboratory. Its easy-to-follow display, ergonomically-placed operating buttons, ... dispensing, reverse pipetting and diluting make this ... simple functions of a manual pipette without ...
Inquire...
Medicine Products: